Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.14
-0.0300-0.95%
Post-market: 3.140.00000.00%19:58 EST
Volume:4.30M
Turnover:13.46M
Market Cap:750.66M
PE:-5.86
High:3.18
Open:3.18
Low:3.10
Close:3.17
52wk High:4.18
52wk Low:0.6925
Shares:239.06M
Float Shares:237.00M
Volume Ratio:0.80
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5358
EPS(LYR):-0.2764
ROE:97.76%
ROA:-5.42%
PB:-1.66
PE(LYR):-11.36

Loading ...

Esperion Receives $90 Million Payment as Otsuka Launches NEXLETOL in Japan

Reuters
·
Nov 21, 2025

Esperion Partner Otsuka Launches Nexletol® in Japan for the Treatment of Hypercholesterolemia

THOMSON REUTERS
·
Nov 21, 2025

Esperion Therapeutics: Under Agreement, Esperion Will Receive $90 Mln in a Near Term Payment as a Result of the Recent Otsuka Achievements

THOMSON REUTERS
·
Nov 21, 2025

Esperion Therapeutics: Also Eligible to Receive Additional Sales Milestone Payments Based on Total Net Sales Achievements by Otsuka in Japan

THOMSON REUTERS
·
Nov 21, 2025

Esperion Therapeutics Says Health Canada Grants Marketing Approval for Nilemdo

MT Newswires Live
·
Nov 18, 2025

Health Canada Approves Esperion’s NILEMDO for LDL-Cholesterol Reduction in At-Risk Canadians

Reuters
·
Nov 18, 2025

Esperion Therapeutics Inc -Commercial Launch for Nilemdo Is Expected in Q2 2026

THOMSON REUTERS
·
Nov 18, 2025

HLS Therapeutics Inc - Commercial Launch Expected in Q2 2026

THOMSON REUTERS
·
Nov 18, 2025

Esperion Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer John B. Harlow Jr

Reuters
·
Nov 18, 2025

Stock Track | Esperion Therapeutics Soars 5.26% as New Data Shows NEXLETOL Reduces Cardiovascular Events and Blood Clots

Stock Track
·
Nov 10, 2025

Esperion Reports Bempedoic Acid Cuts Major Cardiovascular Events and Venous Thromboembolism in CLEAR Outcomes Study

Reuters
·
Nov 10, 2025

Esperion Announces New Data From Clear Outcomes Highlighting Value of Nexletol® (Bempedoic Acid) in Oral and Poster Presentations at the Aha Scientific Sessions 2025

THOMSON REUTERS
·
Nov 10, 2025

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

GlobeNewswire
·
Nov 10, 2025

Esperion Therapeutics Grants 77,650 RSUs to New Employees Under Inducement Plan

Reuters
·
Nov 07, 2025

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 07, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 07, 2025

Esperion Q3 revenue up 69% on prescription volumes

Reuters
·
Nov 06, 2025

Stock Track | Esperion Therapeutics Plunges 6.12% Pre-market on Disappointing Q3 Earnings

Stock Track
·
Nov 06, 2025

Stock Track | Esperion Therapeutics Plunges 6.12% Pre-Market on Disappointing Q3 Earnings

Stock Track
·
Nov 06, 2025

Esperion Therapeutics Q3 EPS $(0.16) Misses $(0.08) Estimate, Sales $87.309M Beat $77.803M Estimate

Benzinga
·
Nov 06, 2025